The content on this site is intended for healthcare professionals only
Dr Andrew Epstein and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from the ASPECT trial.
This was a phase III randomised trial in which Barrett’s oesophagus patients at a high risk of developing high-grade dysplasia or oesophageal cancer were treated with high dose proton pump inhibitors and aspirin.
For more on these findings, watch Prof Jankowski present this data in the press conference here, watch Prof Jankowskis interview with ecancer here, or read news coverage here.
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
